Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...
Muhammed A. Moukhtar Hammad, MBBCh, outlines key findings from a study evaluating testosterone replacement therapy and hearing-related outcomes. Testosterone therapy was not associated with an ...
An expert discusses how the greatest unmet need in minimally invasive benign prostatic hyperplasia (BPH) treatments is achieving durability and retreatment rates that match those of surgical options ...
Modern visualization tools have reduced fluoroscopy use, enhancing direct visualization in kidney stone procedures. Single-use ureteroscopes offer superior deflection and image quality, though cost ...
Krambeck highlights that FANS combine enhanced maneuverability and effective fragment evacuation, leading to higher stone clearance rates and improved procedural outcomes in endourology. In this video ...
The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 mg/m2 docetaxel regimen. Despite a higher cumulative docetaxel dose, the 50 ...
"The CF for 2025 is proposed to decrease to $32.36 from $33.29 in 2024. This is a decrease of 2.80%," write Jonathan Rubenstein, MD, and Mark Painter. On July 10, 2024, the Centers for Medicare & ...
VIR-5500 targets PSMA and is being tested in a phase 1 trial for mCRPC, including combination therapy with ARPIs. Interim data showed PSA reductions in all patients and a favorable safety profile, ...
SBRT post-radical prostatectomy showed favorable 4-year BCRFS and manageable safety, offering a faster alternative to conventional radiotherapy. SBRT demonstrated a lower risk of biochemical ...
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025. Host Amy Pearlman, MD, discusses premature ejaculation with Brian L. Steixner, MD, a ...
Andrea Necchi, MD, reported a pCR rate of 38% (95% CI: 28-49) for cohort 1 vs 28% (95% Ci: 16-44) for cohort 2. The median progression-free survival was 15.7 months with the combination of lenvatinib ...
Aleece Fosnight, MSPAS, PA-C, highlights that although urinary leakage is common, it is not normal—and effective treatment options exist. In this interview, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback